Family history of liver cancer may modify the association between HBV infection and liver cancer in a Chinese population.
family history
hepatitis B Virus
hepatocellular carcinoma
interaction
serological marker
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
12
04
2019
revised:
07
06
2019
accepted:
08
06
2019
pubmed:
23
6
2019
medline:
18
9
2020
entrez:
23
6
2019
Statut:
ppublish
Résumé
The potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined. We conducted a population-based case-control study composed of 2011 liver cancer cases and 7933 controls in Jiangsu province, China from 2003 to 2010. Data on major risk or protective factors were collected and HBV/HCV sero-markers were assayed using blood samples. Semi-Bayes (SB) adjustments were applied to provide posterior estimates. Both family history of liver cancer (adjusted odds ratios [OR]: 4.32, 95% confidence intervals [CI]: 3.25-5.73) and hepatitis B surface antigen (HBsAg) positivity (adjusted OR: 9.94, 95% CI: 8.33-11.87) were strongly associated with liver cancer development. For individuals with different combinations of serological markers, the adjusted ORs were 8.45 (95% CI: 5.16-13.82) for HBsAg- and HBcAb-positive; 7.57 (95% CI: 4.87-11.77) for HBsAg-, HBeAg- and HBcAb-positive; and 3.62 (95% CI: 2.47-5.31) for HBsAg-, HBeAb- and HBcAb-positive, compared to all negatives in HBV serological markers. One log increase in HBV DNA level was associated with 17% increased risk (adjusted OR: 1.17, 95% CI: 1.03-1.32). The SB-adjusted OR of HBV-positive individuals with family history of liver cancer was 41.34 (95% posterior interval [PI]: 23.69-72.12) compared with those HBV-negative without family history. Relative excess risk due to additive interaction, the attributable proportion and synergy index were 73.13, 0.87 and 8.04 respectively. Adjusted ratio of OR for multiplicative interaction was 2.84 (95% CI: 1.41-5.75). Super-additive and super-multiplicative interactions may exist between family history of liver cancer and HBV infection on the development of liver cancer.
Sections du résumé
BACKGROUND & AIMS
The potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined.
METHODS
We conducted a population-based case-control study composed of 2011 liver cancer cases and 7933 controls in Jiangsu province, China from 2003 to 2010. Data on major risk or protective factors were collected and HBV/HCV sero-markers were assayed using blood samples. Semi-Bayes (SB) adjustments were applied to provide posterior estimates.
RESULTS
Both family history of liver cancer (adjusted odds ratios [OR]: 4.32, 95% confidence intervals [CI]: 3.25-5.73) and hepatitis B surface antigen (HBsAg) positivity (adjusted OR: 9.94, 95% CI: 8.33-11.87) were strongly associated with liver cancer development. For individuals with different combinations of serological markers, the adjusted ORs were 8.45 (95% CI: 5.16-13.82) for HBsAg- and HBcAb-positive; 7.57 (95% CI: 4.87-11.77) for HBsAg-, HBeAg- and HBcAb-positive; and 3.62 (95% CI: 2.47-5.31) for HBsAg-, HBeAb- and HBcAb-positive, compared to all negatives in HBV serological markers. One log increase in HBV DNA level was associated with 17% increased risk (adjusted OR: 1.17, 95% CI: 1.03-1.32). The SB-adjusted OR of HBV-positive individuals with family history of liver cancer was 41.34 (95% posterior interval [PI]: 23.69-72.12) compared with those HBV-negative without family history. Relative excess risk due to additive interaction, the attributable proportion and synergy index were 73.13, 0.87 and 8.04 respectively. Adjusted ratio of OR for multiplicative interaction was 2.84 (95% CI: 1.41-5.75).
CONCLUSIONS
Super-additive and super-multiplicative interactions may exist between family history of liver cancer and HBV infection on the development of liver cancer.
Identifiants
pubmed: 31228882
doi: 10.1111/liv.14182
pmc: PMC6705127
mid: NIHMS1045272
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1490-1503Subventions
Organisme : NCI NIH HHS
ID : T32 CA009142
Pays : United States
Organisme : NIEHS NIH HHS
ID : R21 ES011667
Pays : United States
Organisme : NINR NIH HHS
ID : K01 NR017852
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI035040
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW000013
Pays : United States
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Int J Cancer. 2018 Apr 15;142(8):1560-1567
pubmed: 29193051
Zhonghua Gan Zang Bing Za Zhi. 2009 Dec;17(12):930-4
pubmed: 20038336
Intervirology. 2010;53(2):111-8
pubmed: 19955816
Int J Epidemiol. 2007 Feb;36(1):195-202
pubmed: 17329317
IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438
pubmed: 15285078
World J Gastroenterol. 2016 Nov 7;22(41):9069-9095
pubmed: 27895396
Clin Gastroenterol Hepatol. 2013 Dec;11(12):1636-45.e1-3
pubmed: 23669307
JAMA. 2006 Jan 4;295(1):65-73
pubmed: 16391218
Zhonghua Yi Xue Za Zhi. 2012 Jul 17;92(27):1874-7
pubmed: 23134955
Carcinogenesis. 2008 Jan;29(1):106-12
pubmed: 17999990
Cancer Lett. 2009 Dec 1;286(1):9-14
pubmed: 19091458
J Gastroenterol Hepatol. 2011 Apr;26(4):628-38
pubmed: 21323729
Liver Int. 2005 Apr;25(2):220-5
pubmed: 15780042
J Gastroenterol Hepatol. 1995 Nov-Dec;10(6):674-82
pubmed: 8580413
Int J Cancer. 2014 Oct 1;135(7):1605-14
pubmed: 24535817
Eur J Cancer Prev. 2018 May;27(3):205-212
pubmed: 29489473
Lancet. 1999 Apr 10;353(9160):1253-7
pubmed: 10217098
Asian Pac J Cancer Prev. 2013;14(12):7251-6
pubmed: 24460283
Cancer. 2004 Sep 1;101(5):1009-17
pubmed: 15329910
Scand J Gastroenterol. 2010;45(2):243-9
pubmed: 20095888
J Gastroenterol Hepatol. 2004 Jun;19(6):670-5
pubmed: 15151623
IARC Monogr Eval Carcinog Risks Hum. 2010;96:3-1383
pubmed: 21735939
World J Gastroenterol. 2005 Jul 28;11(28):4431-4
pubmed: 16038048
Eur J Epidemiol. 2005;20(7):575-9
pubmed: 16119429
J Natl Cancer Inst. 2005 Feb 16;97(4):265-72
pubmed: 15713961
Cancer Genet. 2017 Oct;216-217:37-51
pubmed: 29025594
Zhonghua Liu Xing Bing Xue Za Zhi. 2010 Jul;31(7):721-6
pubmed: 21162830
J Gastroenterol Hepatol. 2001 Nov;16(11):1274-81
pubmed: 11903747
Hepatology. 2012 May;55(5):1416-25
pubmed: 22095619
J Hepatol. 2005 Feb;42(2):218-24
pubmed: 15664247
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Vaccine. 2009 Nov 5;27(47):6550-7
pubmed: 19729084
J Clin Oncol. 2008 Jan 10;26(2):177-82
pubmed: 18182659
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441
pubmed: 23189750
Zhonghua Liu Xing Bing Xue Za Zhi. 2011 Sep;32(9):888-91
pubmed: 22340876
Eur J Cancer Prev. 2017 Jul;26(4):357-364
pubmed: 27275735
Oncotarget. 2016 Aug 2;7(31):49299-49309
pubmed: 27384478